30,000 People will Take Part in Post-registration Trials of COVID-19 Vaccine of Vector Center

07 October 2020

GMP News

Nearly 30,000 volunteers will take part in post-registration trials of the coronavirus vaccine developed by Russia’s Vector State Research Center of Virology and Biotechnology, the press service of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing told TASS.

“After the vaccine’s registration the centers of carrying out post-registration trials will be selected, and 30,000 volunteers will take part in them,” the statement said.

The vaccine’s registration procedure is due to be over by October 15.

Medical institutions will receive the vaccine once its mass production is launched.

Earlier, the press service of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing told that the post-registration trials of the vaccine would begin in November-December 2020 after the first series of the medication are received.

Source

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more